INSM · INSMED Inc
$123.74
-2.59 (-2.05%)
At close · Aug 14
Market Cap
$27.02B
Shares
218.38M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$123.74
Open$125.67
Day$122.21–126.85
52W close$91.88–211.41
Avg vol 30d3.0M
Short int11.4M · 5.2% float · 5.1d
Short vol29%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
+15%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
27%
mid-range
Momentum
relative strength
1-month return
+14%
trailing
6-month return
−22%
trailing
YTD return
−29%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $108 › 200d $145 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +114 funds added
Insider flow
Distributing
Net -$33.5M over 90 days · 100% sells
Short interest
Falling
5.20% of float · ▼ -2.4% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
655 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
EPS growth
−15%
Y/Y
Free cash flow
$-967.6M
Balance sheet
$33.6M
net debt
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
full-year 2026
BRINSUPRI revenues
$1.25B – $1.4B
ARIKAYCE revenues
$450M – $470M
peak
TPIP peak revenue estimate
at least $6B
ARIKAYCE peak revenue estimate
at least $1B
BRINSUPRI peak revenue estimate
at least $7B
Combined peak sales of three lead programs
at least $14B
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2024
Global revenue guidance
· full year 2024
$340M – $360M
Guided vs delivered
· last 1 settled
Full year 2024 global revenue
full year 2024
guided $340M – $360M
$363.71M
Beat +3.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
+15%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
27%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $108 › 200d $145 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +114 funds added
Insider flow
Distributing
Net -$33.5M over 90 days · 100% sells
Short interest
Falling
5.20% of float · ▼ -2.4% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
655 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $92
Now $124 · 27%
Range high $211
vs 200-day avg -15%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ARIKAYCE global revenue growth | 8% | the second quarter of 2026 compared to the second quarter of 202 | — |
|
|
|||
| ARIKAYCE revenue | $116.3M | Q2 2026 | +8.3% |
|
|
|||
| BRINSUPRI global revenue growth | 49% | the second quarter of 2026 compared to the first quarter of 2026 | — |
|
|
|||
| BRINSUPRI revenue | $309.2M | Q2 2026 | — |
|
|
|||
| Cash, cash equivalents, and marketable securities | $1.2B | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INSM
this stock
INSMED Inc
|
$27.02B | -28.9% | +66.7% | — | 5.2% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INSM | -5.6% | +14.2% | -22.2% | +25.5% | -28.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -6.0% | +9.8% | -36.0% | +21.6% | -42.8% |
Key facts
CIK
1104506
CUSIP
457669307
13F (30d)
609 filings
602 filers
Visit website
Investor relations